Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer
PSCA CAR-Vδ1 γδ T cells represent a potent and safe therapeutic modality for PSCA<sup>+</sup> PC, with efficacy comparable to other CAR T cell types and potential advantages in safety and persistence. These findings support further development of CAR-Vδ1 T cell immunotherapy for solid tumors.
Authors
- Zhiyao Li (ORCID: https://orcid.org/0009-0007-3472-9448)
- Xiaolei Sun (ORCID: https://orcid.org/0000-0002-5260-379X)
- Ningyuan Liu (ORCID: https://orcid.org/0000-0002-0374-967X)
- Michael A. Caligiuri (ORCID: https://orcid.org/0000-0002-4095-3020)
- Jianhua Yu (ORCID: https://orcid.org/0000-0002-0326-3223)
- Lei Tian (ORCID: https://orcid.org/0000-0002-9051-9468)
- Jianying Zhang (ORCID: https://orcid.org/0000-0001-5896-9509)
- Zhixin Li (ORCID: https://orcid.org/0000-0001-9962-3942)
- Lewei Jin
- Zahir Shah (ORCID: https://orcid.org/0000-0003-2251-7601)
Institutions
- City Of Hope National Medical Center (US)
- University of California, Irvine (US)
- Precision Therapeutics (United States) (US)
- City of Hope (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/jitc-2025-011890
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27